Alio Jorge L, Rodriguez Alejandra E, Ferreira-Oliveira Renan, Wróbel-Dudzińska Dominika, Abdelghany Ahmed A
Department of Cornea and Refractive Surgery, VISSUM, Alicante, Spain.
Division of Ophthalmology, Universidad Miguel Hernández, Alicante, Spain.
Ophthalmol Ther. 2017 Dec;6(2):285-293. doi: 10.1007/s40123-017-0100-z. Epub 2017 Aug 8.
The objective of this study was to evaluate the use of autologous platelet-rich plasma (PRP) eye drops as monotherapy for the treatment of moderate to severe cases of dry eye disease.
Three hundred and sixty-eight patients with moderate to severe dry eye disease (DED) were included in this prospective case series. Subjects were classified as evaporative DED (EDED) or aqueous deficient DED (ADDED). Improvement of the DED subjective symptoms, corneal fluorescein staining (CFS), and corrected distance visual acuity (BCVA) were evaluated. We also analysed how many rounds of PRP therapy were used.
Two hundred and ninety-seven (80.7%) patients were women, and 71 (19.3%) were men. Two hundred and thirty-two (63%) patients had EDED, while 136 (37%) had ADDED. After 6 weeks of monotherapy treatment with autologous PRP, dry eye symptoms improved in 322 (87.5%) cases. A decrease of CFS was observed in 280 (76.1%) patients. One hundred and six (28.8%) patients improved at least 1 line of BCVA. The scores in the ocular Surface Disease Index and the Oxford scale of corneal fluorescein staining decreased statistically after the treatment (p < 0.05).
The topical use of autologous platelet-rich plasma as monotherapy is an effective treatment to improve signs and symptoms in patients suffering from moderate to severe chronic DED.
本研究的目的是评估自体富血小板血浆（PRP）滴眼液作为单一疗法治疗中度至重度干眼症的效果。
本前瞻性病例系列纳入了368例中度至重度干眼症患者。受试者被分为蒸发过强型干眼症（EDED）或泪液分泌不足型干眼症（ADDED）。评估干眼症主观症状、角膜荧光素染色（CFS）和矫正远视力（BCVA）的改善情况。我们还分析了使用了多少轮PRP治疗。
297例（80.7%）患者为女性，71例（19.3%）为男性。232例（63%）患者为EDED，136例（37%）为ADDED。自体PRP单一疗法治疗6周后，322例（87.5%）患者的干眼症状得到改善。280例（76.1%）患者的CFS降低。106例（28.8%）患者的BCVA至少提高了1行。治疗后眼表疾病指数和牛津角膜荧光素染色量表的评分有统计学意义的下降（p<0.05）。
局部应用自体富血小板血浆作为单一疗法是改善中度至重度慢性干眼症患者体征和症状的有效治疗方法。
